StockWatch
·
HomeLiveReports
Biotechnology: Pharmaceutical Preparations
Clinical TrialApr 27, 2026, 07:18 AM

PPBT Announces New Data from CAPTN-3 Platform Tri-specific IM1240

AI Summary

Purple Biotech Ltd. announced new data from its CAPTN-3 Platform Tri-specific IM1240. This information was disclosed in a press release issued on April 27, 2026, and filed as an exhibit to a Form 6-K report.

Key Highlights

  • Purple Biotech announced new data from its CAPTN-3 Platform Tri-specific IM1240.
  • The announcement was made via a press release issued on April 27, 2026.
View SEC Filing
PPBT
Biotechnology: Pharmaceutical Preparations
PURPLE BIOTECH LTD.

Price Impact

More from PPBT

Clinical TrialAug 10, 4:12 PM

Purple Biotech's IM1240 to Enter Clinic 2027; $6.1M Cash

Quarterly ResultAug 7, 7:08 AM

Purple Biotech Q2 2026 Net Income $0.4M; IM1240 Clinical Entry in 2027

Quarterly ResultAug 7, 7:07 AM

Purple Biotech Q2 Net Income $0.4M; Cash $6.1M, Runway to Mid-2027

More in Clinical Trial

NTHIAug 13, 5:28 PM

NEONC Technologies NEO100-01 Phase 2a shows 26.1-month OS in glioma

MSLEAug 13, 5:04 PM

Satellos Bioscience Gets FDA Fast Track; Positive Phase 2 DMD Data

ELDNAug 13, 4:07 PM

Eledon Pharmaceuticals to advance tegoprubart into Phase 3 kidney trial